semaglutide oral cardiovascular indication news 2025 Early uptake of Wegovy pill Oral semaglutide reduces risk of

since then, states have been redetermining Medicaid enrollment every 12 months

These medicines work by harnessing gut-brain hormonal pathways to reduce appetite and change food intake behaviour, a far more targeted approach than telling patients only to eat less and move more

Here is a direct comparison from published Phase 2 and Phase 3 data: Semaglutide (Ozempic/Wegovy): Average weight loss of 14.9% at 68 weeks in the STEP 1 trial Tirzepatide (Mounjaro): Average weight loss of 20.9% at 72 weeks in the SURMOUNT-1 trial Retatrutide: Average weight loss of 24.2% at 48 weeks in the Phase 2 trial Retatrutide reached a higher percentage of weight loss in fewer weeks

Featured reviews Real Patients, Real Results What if I dont want to lose too much weightcan I control it